Correlation between particle size, in vivo particle persistence, and lung injury.
Dosimetry parameters such as deposition, clearance, retention, and translocation and dissolution of inhaled particles in and to different lung compartments may be important for the persistence of particles in the lung and may correlate with adverse pulmonary effects. We investigated such correlations using a model involving TiO2 particles of two particle sizes (20 nm diameter, ultrafine; 250 nm diameter, fine) of the same crystalline structure (anatase). A 12-week inhalation experiment in rats resulted in a similar mass deposition of the two particle types in the lower respiratory tract. The ultrafine particles elicited a persistently high inflammatory reaction in the lungs of the animals compared to the larger-sized particles. In the postexposure period (up to 1 year) retention in the alveolar space per se was not different between fine and ultrafine TiO2. However, the following differences between the particle types were noted: a significantly different total pulmonary retention, both quantitatively (significantly prolonged retention of the ultrafine TiO2) and qualitatively (increased translocation to the pulmonary interstitium and persistence there of the ultrafine TiO2); greater epithelial effects (Type II cell proliferation; occlusion of pores of Kohn) and the beginning of interstitial fibrotic foci with ultrafine TiO2; significant sustained impairment of alveolar macrophage function after ultrafine TiO2 exposure as measured by the clearance of test particles. A correlation between particle surface area and effects was observed. A comparison of the adverse reactions with dosimetric parameters of TiO2 in different lung compartments in the postexposure period showed a correlation of the persistence of effects in both the alveolar and interstitial space with the persistence of particles in the respective compartment.
Oberdörster
G
G
University of Rochester, Department of Environmental Medicine, New York 14642.
Ferin
J
J
Lehnert
B E
BE
D000280:Administration, Inhalation; D000818:Animals; D004305:Dose-Response Relationship, Drug; D008171:Lung Diseases / Q000209:etiology* / Q000378:metabolism / Q000473:pathology; D016676:Macrophages, Alveolar / Q000378:metabolism; D008297:Male; D008657:Metabolic Clearance Rate; D010316:Particle Size; D011014:Pneumonia / Q000209:etiology / Q000378:metabolism / Q000473:pathology; D051381:Rats; D011916:Rats, Inbred F344; D014025:Titanium / Q000493:pharmacokinetics*
C009495:titanium dioxide; D014025:Titanium